Brokers

Brokers Issue Forecasts for Astria Therapeutics, Inc.’s Q1 2023 Earnings (NASDAQ:ATXS)


Astria Therapeutics, Inc. (NASDAQ:ATXSGet Rating) – Equities researchers at Wedbush issued their Q1 2023 earnings estimates for shares of Astria Therapeutics in a research note issued to investors on Friday, May 13th. Wedbush analyst L. Chico anticipates that the biotechnology company will post earnings per share of ($0.72) for the quarter. Wedbush also issued estimates for Astria Therapeutics’ Q2 2023 earnings at ($0.79) EPS, Q3 2023 earnings at ($0.90) EPS and Q4 2023 earnings at ($0.81) EPS.

Astria Therapeutics (NASDAQ:ATXSGet Rating) last released its earnings results on Thursday, May 12th. The biotechnology company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.34).

Other equities research analysts have also recently issued research reports about the company. Zacks Investment Research cut Astria Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Astria Therapeutics in a research note on Friday, March 11th.

NASDAQ:ATXS opened at $4.10 on Monday. The stock has a market cap of $53.37 million, a PE ratio of -0.52 and a beta of 1.38. The stock’s 50-day moving average is $6.27 and its two-hundred day moving average is $6.06. Astria Therapeutics has a fifty-two week low of $3.83 and a fifty-two week high of $15.72.

Institutional investors have recently made changes to their positions in the business. GSA Capital Partners LLP bought a new stake in Astria Therapeutics during the third quarter worth approximately $221,000. Commodore Capital LP bought a new stake in Astria Therapeutics during the third quarter worth approximately $2,115,000. Oppenheimer & Co. Inc. bought a new stake in Astria Therapeutics during the third quarter worth approximately $108,000. Artal Group S.A. bought a new stake in Astria Therapeutics during the third quarter worth approximately $295,000. Finally, BlackRock Inc. bought a new stake in Astria Therapeutics during the third quarter worth approximately $363,000. 51.79% of the stock is owned by hedge funds and other institutional investors.

About Astria Therapeutics (Get Rating)

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema.

Featured Stories

Earnings History and Estimates for Astria Therapeutics (NASDAQ:ATXS)



Receive News & Ratings for Astria Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Astria Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.